Loading...

NAMS NEWAMSTERDAM PHARMA CO NV Expansion Plans 8-K Filing

NWMS

NMS

NEWAMSTERDAM PHARMA CO NV

(NAMS)

2025 8-K

Quarterly Update

Director Departure

Corporate Update

Corporate Update

Financial Update

Financial Update

Investor Presentation Update

EMA Approval Update

Supply Agreement Signed

Financial Statements

New Product Launches

Investor Meetings

New Product Launches

Financial Statements

Product Expansion

Board Appointment

Financial Results

2024 Milestones

Public Offering

Share Sale Termination

Positive Trial Results

Positive Trial Results

Clinical Trial Update

Financial Results

Financial Restatement

Sales Agreement Amendment

Earnings Reports

Phase 3 BROOKLYN clinical t...

Resignation and Appointments

Patent Issuance

Shareholder Meeting Results

Earnings Reports

Appointment and Resignation

Regulation FD Disclosure

Earnings Release

Underwriting Agreement for ...

Regulation FD Disclosure

Appointment of Chair of the...

Regulation FD Disclosure

External Links:

On May 7, 2025, NewAmsterdam Pharma Co N.V. reported positive results from its Phase 3 clinical trials, showing that its drug, obicetrapib, significantly reduces lipoprotein(a) levels by 45% and lowers LDL cholesterol by over 64%, suggesting its potential in cardiovascular disease treatment.

AI Assistant

NEWAMSTERDAM PHARMA CO NV

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.